Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Kwong

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Orthopaedic Practice|May 15, 2015
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patientsLouis Kwong, Alexander G G Turpie
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 22, 2006
Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgerySean D Sullivan, Louis Kwong, Edith Nutescu
Current Medical Research and Opinion|January 4, 2011
Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgeryOnur Baser, Dylan Supina, Nishan Sengupta, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 20, 2010
Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgeryOnur Baser, Dylan Supina, Nishan Sengupta, et al.
Physician Leadership Journal|February 2, 2019
BUILDING PHYSICIANS WITH SELF-AWARENESSRachel M Randall, Louis Kwong, Thomas Kuivila, et al.
Therapeutic Advances in Musculoskeletal Disease|October 31, 2019
A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritisAlan Kivitz, Louis Kwong, Tammi Shlotzhauer, et al.
Journal of Medical Economics|October 26, 2011
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Pharmacoeconomics|December 23, 2011
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Rheumatology and Therapy|March 8, 2022
A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip OsteoarthritisAlan Kivitz, Purvi Mehra, Peter Hanson, et al.
Drugs in R&D|August 5, 2021
Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized StudyPeter Hanson, Alan Kivitz, Purvi Mehra, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Orthopaedic Practice|May 15, 2015
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patientsLouis Kwong, Alexander G G Turpie
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 22, 2006
Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgerySean D Sullivan, Louis Kwong, Edith Nutescu
Current Medical Research and Opinion|January 4, 2011
Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgeryOnur Baser, Dylan Supina, Nishan Sengupta, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 20, 2010
Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgeryOnur Baser, Dylan Supina, Nishan Sengupta, et al.
Physician Leadership Journal|February 2, 2019
BUILDING PHYSICIANS WITH SELF-AWARENESSRachel M Randall, Louis Kwong, Thomas Kuivila, et al.
Therapeutic Advances in Musculoskeletal Disease|October 31, 2019
A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritisAlan Kivitz, Louis Kwong, Tammi Shlotzhauer, et al.
Journal of Medical Economics|October 26, 2011
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Pharmacoeconomics|December 23, 2011
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Rheumatology and Therapy|March 8, 2022
A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip OsteoarthritisAlan Kivitz, Purvi Mehra, Peter Hanson, et al.
Drugs in R&D|August 5, 2021
Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized StudyPeter Hanson, Alan Kivitz, Purvi Mehra, et al.
Pageof 1